Kratom (Mitragyna speciosa) has emerged as a complex public health challenge across Ohio, requiring multidisciplinary healthcare teams to understand its distinct pharmacology, shifting legal status, and clinical health risks. The plant functions as a mild stimulant at lower doses and produces opioid-like analgesia, sedation, and euphoria at higher doses. Newer high-potency extracts, concentrated liquids, and synthetic derivatives significantly heighten risks of physical dependence, tolerance, severe withdrawal, and acute organ toxicity. Individuals increasingly turn to these products to self-manage chronic pain, anxiety, depression, or opioid withdrawal, often without disclosing consumption to healthcare providers. The intersection of kratom use and behavioral and physical health crises is driven by a cycle of self-medication and severe intoxication and withdrawal dynamics.